CARSON CITY, Nev., Oct. 19, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced ...
Blinded Phase 3 data of NE3107 in Alzheimer's appear to indicate robust cognitive and biomarker efficacy. Market is significantly undervaluing the probability of a successful data unblinding expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback